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Medicine, and the healthcare professions generally,
has always had a vexed relationship with the placebo.
Was it Hippocrates, or was it Galen, who enjoined
physicians to use new medicines while they still had the
power to heal – acknowledging that something other
than the intrinsic properties of drugs was critical to their
success? In any event, long before Pepper (1) and
Beecher (2) drew professional attention to placebo
effects, scientific physicians appreciated the importance
of belief and suggestion in curing disease (for
comprehensive coverage of placebo effects and related
topics, see 3-7). It was not long ago that placebo pills,
labeled as such, were listed in the Physicians Desk
Reference. Norman Cousins (8) famously advocated
placebo effects in medicine at roughly the same time
that the randomized clinical trial – still the gold standard
for evidence-based treatment – effectively consigned
the placebo effect to the status of a nuisance variable
which must be overcome, instead of a catalyst to be
capitalized on. The New York Times Magazine
announced on its cover (January 9, 2000) the
“astonishing fact” that “placebos work”. But only a year
later, not content merely to show that effective
treatments are better than placebo, Hrobjartsson and
Gotzsche (9,10) concluded that placebos had virtually
no practical effects on clinical outcome – leading the
Wall Street Journal, in a May 30, 2001 commentary, to
criticize the “Dale Carnegie school of medical thought”.
Nevertheless, the New York Times recently reported
(May 27, 2008) that a Maryland-based company,
Efficacy Brands, proposed to market a cherry-flavored
placebo named Obecalp (read it backwards) over the
counter to reduce the use of active medications for
children with minor ills, hypochondriasis, and other
forms of abnormal illness behavior.
Why are placebos so controversial? In part, I think, it
is because they appear to challenge the biological basis
of medical practice. Beginning with the microbe-
hunting of Pasteur and Koch, through the
pharmaceutical revolution, the development of
laboratory diagnostics and imaging techniques, and
pharmacogenomics, a major trend in the scientific
revolution in medicine has been the development of
diagnostic and therapeutic techniques that minimize
human interaction between physician and patient.
Elsewhere, I have cited the “feinberger”, the hand-
scanner used on Star Trek to diagnose and treat illness,
as the apparent ideal for scientific medicine, because it
obviates the need to take account of any psychosocial
dimension of illness, prevention, or treatment (11).
Scientific medicine, in this exclusively biocentric view,
is simply a matter of treating germs with pills.
But the behavioral and social sciences are sciences
too, and the placebo and related effects underscore the
psychosocial dimensions of illness, prevention, and
treatment: of the effect of the patient’s (and the
physician’s) beliefs, attitudes, and expectations on the
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effects of those pills; on the role of human judgment in
assessing symptoms, reading test results, making
diagnoses, and choosing treatments; on the
intrapersonal and interpersonal determinants of
compliance, the importance of physician-patient
communication and social support on treatment
outcomes; the relationship between social class (and
social status) and health. You can make a pill to treat an
illness – that’s a matter of understanding the biology,
but then you’ve got to get the patient to take the pill –
and that is a matter of psychology and social science.
The fact that Hrobjartsson and Gotszche, searching
the entire medical literature, were able to find only 114
studies that compared placebo to a no-treatment control
is powerful testimony to the widespread lack of interest
in the placebo effect as an effect – an effect that can be
added to the specific effects of prescription drugs or
other biological treatments. In the treatment of pain, for
example, big, dark-colored, bad-tasting placebos are
more effective than small, brightly colored, good tasting
ones; placebos delivered intravenously are more
effective than placebos delivered intramuscularly,
which in turn are more effective than placebos delivered
orally (12). And it appears that the effect of a placebo
was a constant proportion of that of the active agent to
which it was compared: placebo believed to be aspirin
is roughly 55% as effective as real aspirin, but placebo
believed to be morphine is roughly 55% as effective as
real morphine (12). More recently, we have learned that
expensive placebos are more effective than cheap ones
(13). At the very least, results such as these suggest how
genuine medications ought to be marketed, if we are to
maximize their effectiveness.
Wampold and his colleagues suggest that placebo
effects will be greatest with psychological as opposed to
physical disorders – that is, for disorders like depression
rather than for cancer or heart disease; and, in the case
of physical disorders, when the endpoint is
psychological rather than in nature – that is, for anxiety,
or depression or pain rather than for coronary
cardiovascular disease or for cancer (14). The
implication is that the placebo effect, being
“psychological” in nature, will work only on the
psychological dimensions of health and disease.
Certainly, there seems to be a huge placebo component
in the treatment of certain psychiatric disorders, such as
depression (15, 16). But at the same time, the medical
literature is littered with convincing demonstrations that
patients’ beliefs and expectations can moderate drug
and other biological effects on objective as well as
subjective endpoints. In one recent study, for example,
Parkinson’s disease patients experienced higher degrees
of motor control when they were told they were
receiving electrical stimulation of the subthalamic
nucleus than when the stimulation was delivered
without their knowledge (17). So much for the
feinberger. Paraphrasing the advertisements for
Nexium™, future research needs to distinguish between
two types of endpoints: subjective endpoints –feeling
better – and objective– getting better.
Placebo effects have been called the “crown jewel” of
psychosomatic medicine, because they reveal the
effects of mental states -- attitudes, beliefs, and
expectations -- on physical outcomes. Psychosomatic
effects, in turn, are in bad odor among some segments
of the medical community for the same reason that
placebo effects are: the proposition that psychosocial
factors might play a causative role in physical illness is
seen as compromising the basis of medicine on
biological science. After Marshall & Warren (18)
identified the role of H. pylori in gastritis and peptic
ulcers (a discovery that earned them the Nobel Prize in
2005), a leading molecular neuropsychiatrist wrote a
commentary entitled “Another One Bites the Dust” (19)
celebrating the triumph of biomedicine over
psychology. But as it turns out, while antibodies for H.
pylori are found in over 90% of ulcer patients, they are
also found in almost 80% of ulcer-free patients,
indicating that “other factors in addition to H. pylori
infection have an important role in the development of
peptic ulcer” (20). Some of these factors are
psychosocial: animal models clearly show a causal role
for psychological stress in the origin of ulcers (21). If
both stress and bacterial infection contribute to gastric
disease, then both deserve appropriate diagnosis and
treatment.
But beyond whatever advantage they can provide in
the treatment of illness, placebos are of theoretical
interest because of the light they can shed on the
problems of mind and body. Usually, the mind-body
problem is framed as unidirectional: how brain
processes can produce conscious mental states. But
placebos, and other psychosomatic effects, remind us
that there is another mind-body problem: how mental
states can affect bodily functioning. Documenting these
effects, and understanding their underlying
psychological and biological mechanisms, is the great
challenge posed by placebos.
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